[A22-04] Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V
Last updated 19.04.2022
Project no.:
A22-04
Commission:
Commission awarded on 18.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with COVID-19 disease who do not require supplemental oxygen and are at increased risk of developing a severe course of COVID-19
Result of dossier assessment:
- Vaccinated patients: added benefit not proven
- Unvaccinated patients: indication of non-quantifiable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-38 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-112 | Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-113 | Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |